JPI 547, also known as NOV 1402, is an oral inhibitor of PARP 1 2 and Tankyrase 1 2. JPI-547 demonstrated anti-tumor activity inBRCA-deficient xenograft models as a single-agent and in combination with chemotherapy and immune checkpoint inhibitors.
SC10914 is a highly potent PARP inhibitor (PARP1 IC50 = 7.87 nM) with potent anti-proliferative activity against human BRCA deficient tumor cells (MDA-MB-436, BRCA1 deficient, IC50 = 4.03 nM, Capan-1 BRCA2 deficient, IC50 = 11.66 nM) and PTEN deficient tumor cells (HGC-27,PTEN deficient, IC50 = 0.35 μM). SC10914 showed potent anti-tumor activity inBRCA1 2 mutant tumor models and better pharmacokinetics profile has the potential to be selected as the clinical candidate for the treatment of treatment of BRCA1 2 deficient cancers.